Copy number variation and clinical response to chemotherapy and bevacizumab in the Czech metastatic colorectal cancer patients
In the pilot study, we found promising copy number variation biomarkers of bevacizumab response in FFPE samples of mCRC patients. The validation phase should be focused especially on the genes associated with angiogenesis (AGRN, MAPK8, ARHGAP22, LGALS13, LGALS4, ZFP36, and MYC), tumorigenesis (DVL1), and tumor proliferation (IFNL1, IFNL2, IFNL3, MAP3K10, and MAP4K1).
Authors
- Lucie Kotková (ORCID: https://orcid.org/0000-0001-7228-7512)
- Radek Trojanec (ORCID: https://orcid.org/0000-0002-2836-7184)
- Jir̆ı́ Drábek (ORCID: https://orcid.org/0000-0002-5747-6478)
- Jana Vrbková (ORCID: https://orcid.org/0000-0002-7830-3058)
- Patrik Flódr (ORCID: https://orcid.org/0000-0002-7982-5229)
- Jana Stránská
- Karolína Bartáková
- Zuzana Rožánková
- Helena Jurtíková
- Barbora Líznerová
Publication Details
- Journal
- Klinicka onkologie
- Published
- 2024-08-15
- DOI
- https://doi.org/10.48095/ccko2024277
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00